Document is current
Any future updates will be listed below
-
Authors
Ueno, Nobuhiro
Sugiyama, Yuya
Kobayashi, Yu
Murakami, Yuki
Iwama, Takuya
Sasaki, Takahiro
Kunogi, Takehito
Takahashi, Keitaro
Tanaka, Kazuyuki
Ando, Katsuyoshi
Kashima, Shin
Inaba, Yuhei
Moriichi, Kentaro
Tanabe, Hiroki
Taruishi, Masaki
Saitoh, Yusuke
Okumura, Toshikatsu
Fujiya, Mikihiro
- License Information
-
More Information
Article History
Received: 25 January 2021
Accepted: 17 June 2021
First Online: 6 August 2021
Declarations
:
: This multicenter prospective observational study was conducted by Asahikawa Kosei General Hospital, Asahikawa City Hospital and Asahikawa Medical University. The protocol was reviewed and approved by the Ethics Committees at Asahikawa Medical University (approved number 15106) and each institution. All patients provided their written informed consent in accordance with the Declaration of Helsinki before commencement of this study.
: Not applicable.
: Y. Sugiyama, Y. Kobayashi, Y. Murakami, T. Iwama, T. Sasaki, T. Kunogi, K. Takahashi, K. Tanaka, K. Ando, S. Kashima, Y. Inaba, K. Moriichi, H. Tanabe and Y. Saitho have no conflicts of interest to declare. N. Ueno has received personal fees from JIMRO Co. Ltd. M. Taruishi has received grants from JIMRO Co. Ltd. T. Okumura has received grants from AbbVie Inc, Astellas Pharma Inc., SHIONOGI Co. Ltd., EISAI co. Ltd. and Hokkaido Welfare Federation of Agricultural Cooperatives. M. Fujiya received grants from JIMRO Co. Ltd., and Kamui Pharma Inc.; grants and personal fees from AbbVie Inc, AYUMI Pharmaceutical Corporation, EA Pharma Co. Ltd., Janssen Pharmaceutical K.K., Kyorin Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Pfizer Inc, Takeda Pharmaceutical Co. Ltd., and ZERIA Pharmaceutical Co. Ltd.; and personal fees from Aspen Japan K.K., Kissei Pharmaceutical Co. Ltd., Olympus Co. Ltd.
